Current status of clinical trials for Alzheimer-type dementia in Japan: strategies to facilitate the development of antidementia drugs.
Several antidementia drugs are currently being developed in Japan. However, although the clinical trial period is one of the most important factors in drug development, it is not always possible to recruit a sufficient number of eligible patients in each facility for two reasons. One is related to the skill of investigators who are requested to undertake the trial, and another is related to the clinical trial system itself. The author outlines the current status of the development of acetylcholinesterase inhibitors as antidementia drugs and discuss the strategies to facilitate the development of antidementia drugs in Japan.
Homma
A
A
Department of Psychiatry, Tokyo Metropolitan Institute of Gerontology, Japan.
D000544:Alzheimer Disease / Q000145:classification / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends*; D003704:Dementia / Q000145:classification / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D007564:Japan; D018579:Patient Selection; D011361:Professional Competence; D012106:Research / Q000639:trends; D012107:Research Design
D002800:Cholinesterase Inhibitors